Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond
Front Oncol
.
2020 Dec 22:10:562219.
doi: 10.3389/fonc.2020.562219.
eCollection 2020.
Authors
Gina Keiffer
1
,
Kimberly L Aderhold
1
,
Neil D Palmisiano
1
Affiliation
1
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
PMID:
33415071
PMCID:
PMC7783448
DOI:
10.3389/fonc.2020.562219
No abstract available
Keywords:
FLT3; acute myeloid leukemia; first line; gilteritinib; midostaurin.